Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
VCEL 
Vericel Corp Ord (VCEL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/12/2025: VCEL (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $55.71
1 Year Target Price $55.71
| 7 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -38.16% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.85B USD | Price to earnings Ratio 140.54 | 1Y Target Price 55.71 |
Price to earnings Ratio 140.54 | 1Y Target Price 55.71 | ||
Volume (30-day avg) 8 | Beta 1.2 | 52 Weeks Range 29.24 - 63.00 | Updated Date 12/15/2025 |
52 Weeks Range 29.24 - 63.00 | Updated Date 12/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.26 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 5.06% | Operating Margin (TTM) 5.11% |
Management Effectiveness
Return on Assets (TTM) 1.05% | Return on Equity (TTM) 4.52% |
Valuation
Trailing PE 140.54 | Forward PE 49.26 | Enterprise Value 1810600910 | Price to Sales(TTM) 7.14 |
Enterprise Value 1810600910 | Price to Sales(TTM) 7.14 | ||
Enterprise Value to Revenue 7 | Enterprise Value to EBITDA 76.12 | Shares Outstanding 50574026 | Shares Floating 50018723 |
Shares Outstanding 50574026 | Shares Floating 50018723 | ||
Percent Insiders 1.05 | Percent Institutions 106.94 |
About Vericel Corp Ord
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 1997-02-04 | CEO, President & Director Mr. Dominick C. Colangelo Esq. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 357 | Website https://www.vcel.com |
Full time employees 357 | Website https://www.vcel.com | ||
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.